Investors
Investor Relations
TSXV:NRX | OTCQB:NRXBF | FSE: J90
Transforming Regenerative Medicine
Nurexone's mission is to pioneer regenerative medicine targeting nerve and tissue regeneration for recovery from Spinal Cord Injuries (SCI), Traumatic Brain Injury (TBI) and a wide variety of indications.
We're developing ExoPTEN, a first nanodrug aimed at motor, sensory and functional recovery form acute spinal cord injury
Get Investor Updates
Latest News
November 27, 2024
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
November 1, 2024
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
Presentations
Latest
Presentation
Fact Sheet
ISEV TECH
AAEV
October 2, 2024
Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries
By Zacks Small Cap Research
Analyst Reports
Events
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
|
27
|
28
|
29
|
30
|
31
|
1
|
2
|
|
3
|
5
|
6
|
7
|
8
|
9
| |
|
10
|
11
|
13
|
14
|
15
|
16
| |
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
